Isolation and characterization of NY-ESO-1-specific T cell receptors restricted on various MHC molecules.

ABSTRACT: Tumor-specific T cell receptor (TCR) gene transfer enables specific and potent immune targeting of tumor antigens. Due to the prevalence of the HLA-A2 MHC class I supertype in most human populations, the majority of TCR gene therapy trials targeting public antigens have employed HLA-A2-restricted TCRs, limiting this approach to those patients expressing this allele. For these patients, TCR gene therapy trials have resulted in both tantalizing successes and lethal adverse events, underscoring the need for careful selection of antigenic targets. Broad and safe application of public antigen-targeted TCR gene therapies will require (i) selecting public antigens that are highly tumor-specific and (ii) targeting multiple epitopes derived from these antigens by obtaining an assortme

SUBMITTER: Bethune MT 

PROVIDER: S-EPMC6233129 | biostudies-literature | 2018 Nov

REPOSITORIES: biostudies-literature